End stage renal disease (Hemodialysis patients) Urological and Genital Diseases Renal disease
Conditions
Interventions
Patient Population: Prevalent HD patients will be entered into two cohorts and followed for 2 years
Cohort 1: patients who receive treatment with HDx using Theranova dialyzers. These p
Sponsors
Renal Therapy Services
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. End stage renal disease 2. Prevalent HD patient defined as having received HD for 90 days or more at the time of the cohort’s inception (01 September 2017 through 30 November 2017) 3. Enrolled in the COREXH registry between 01 September 2017 and 30 November 2017, or were treated via conventional high-flux HD during the same time period at the same renal centers, and with the same model of dialysis care 4. Undergoing HD at least 3 times per week and a minimum duration of 4 hours per session 5. Received dialysis treatment in a renal clinic that meets water quality standards established by the Association for the Advancement of Medical Instrumentation (AAMI)
Exclusion criteria
Exclusion criteria: 1. High comorbidity measured as Charlson comorbidity Index > 8 and patients who were not expected to survive 6 months 2. Metastatic disease 3. Pregnancy 4. Younger than 18 years old
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured using patient records at 2 year follow up: 1. Hospitalization events 2. Days spent in hospital | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured using patient records at 2 year follow up: 1. Mortality 2. Medication consumption | — |
Countries
Colombia
Outcome results
None listed